Prevalence and the impact of hepatitis E infection in pediatric liver transplanted recipients with hepatitis in Thailand

• Published in: Pediatric transplantation 2024-02, Vol.28 (1), p.e14642-n/a
• Main Authors: Sintusek, Palittiya, Khunsri, Siriporn, Chansaenroj, Jira, Thongmee, Thanunrat, Poovorawan, Yong
• Format: Article
• Language: English
• Subjects: Child; Children; Chronic infection; Enzyme-linked immunosorbent assay; Female; Graft rejection; Hepatitis; Hepatitis Antibodies; hepatitis E; Hepatitis E - diagnosis; Hepatitis E - epidemiology; Hepatitis E virus - genetics; Humans; Immunocompromised hosts; Immunoglobulin G; Immunoglobulin M; immunosuppressant; Immunosuppressive agents; Infections; Investigations; Liver transplantation; Male; Patients; Pediatrics; Persistent Infection; Prevalence; Retrospective Studies; Ribonucleic acid; RNA; RNA, Viral - analysis; Serology; Thailand - epidemiology
• ISSN: 1397-3142; 1399-3046
• DOI: 10.1111/petr.14642

Background The hepatitis E virus (HEV) infection typically causes acute and self‐limiting hepatitis. However, chronic infection can occur in immunocompromised hosts. This study determined the prevalence and impact of HEV infection in liver transplanted (LT) children who had transaminitis. Methods The demographic data, anti‐HEV IgM/IgG, serum/stool HEV RNA, and management for LT children with acute or persistent transaminitis from 2003 to 2020 were retrospectively reviewed. HEV serology was tested by ELISA, and HEV RNA was detected by semi‐nested PCR. Results Seventy‐two children with LT with persistent transaminitis with a median age of 4.41 (1.32, 9.14) years (55.6% female) and one with acute hepatitis were investigated for HEV infection. Anti‐HEV IgM, anti‐HEV IgG, serum, or stool HEV RNA was investigated in 95.8% (N = 69), 93.1% (N = 67), 43.1% (N = 31), and 37.5% (N = 27) of patients, respectively. The prevalence of HEV infection was 37.5% (N = 27). There was no significant difference in characteristics between the HEV‐infected and HEV‐non‐infected patients. Moreover, 22.2% (N = 16) and 15.3% (N = 11) of patients had past HEV infection and HEV‐related acute or chronic infection, respectively. Most of the patients had primary treatment as the presumed graft rejection without improvement. In two patients, detectable HEV RNA in serum turned undetectable in approximately 2 weeks and 2 months, and liver enzyme levels normalized after reducing immunosuppressive therapy. Conclusions The prevalence of HEV infection among pediatric LT recipients with hepatitis was high. Chronic HEV infection was evidenced in two patients. Investigations of HEV infection in pediatric LT recipients with persistent transaminitis should guide proper management.